Author: @admin

Post

Melinta Therapeutics Reports Third Quarter 2018 Financial Results

New Product Launches Continue to Make Progress Setting the Stage for Growth in 2019 Entered Commercial Agreement with Menarini Group to market Vabomere®, Orbactiv® and Minocin® for Injection in 68 Countries Outside the U.S. Positive opinion for Vabomere from the CHMP of the European Medicines Agency (EMA), Recommending Approval for Five Indications Implemented Cost Reduction...

Post

Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results

–NUZYRA™ (omadacycline) approved by FDA for the treatment of CABP and ABSSSI — — SEYSARA™ (sarecycline) approved by FDA for the treatment of moderate to severe acne vulgaris — — Company planning for a February 2019 NUZYRA U.S. launch – BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on...

Post

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that on October 31, 2018, the Company granted stock options and restricted stock units to two new employees of the Company. These awards were granted...

Post

Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections

DUBLIN, Ireland , Nov. 01, 2018 (GLOBE NEWSWIRE) —   Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced it has submitted a New Drug Application (NDA) READ FULL TEXT

Post

Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors

NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company has appointed Bruce L. Downey to its Board of Directors. Mr. Downey is an accomplished executive with over 35 years of corporate management,...